Heparin from bovine intestinal mucosa: Glycans with multiple sulfation patterns and anticoagulant effects

Thrombosis and Haemostasis

Volumn 107, Issue 5, 2012, Pages 903-915

  Tovar, Anna M F ^a   Capillé, Nina V M ^a   Santos, Gustavo R C ^a   Vairo, Bruno C ^a   Oliveira, Stephan Nicollas M C G ^a   Fonseca, Roberto J C ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antithrombotic Drug; Bleeding Tendency; Glycosaminoglycan; Serpin; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; DISACCHARIDE; GLUCOSAMINE; HEMOGLOBIN; HEPARIN; IDURONIC ACID; PROTHROMBIN A; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; ANTICOAGULATION; ARTICLE; BLEEDING; CAROTID ARTERY; CONTROLLED STUDY; COW; DISSOCIATION CONSTANT; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOLECULAR SIZE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; SPECTROPHOTOMETRY; SULFATION; SWINE;

EID: 84860508418     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH-11-07-0518     Document Type: Article

References (24)

1. Spyropoulos AC. Brave new world: The current and future use of novel anticoagulants. ThombHaem 2008; 123: S29-S35.
2. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep 2009; 26: 313-321.
3. Mulloy B, Gray E, Barrowcliffe TW. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb Haemost 2000; 84: 1052-1056.
4. Aquino RS, Pereira MS, Vairo BC, et al. Heparins from porcine and bovine intestinal mucosa: Are they similar drugs? ThrombHaemost 2010; 103: 1005-1015.
5. Melo EI, Pereira MS, Cunha RS, et al. Heparin quality control in the Brazilian market: implications in the cardiovascular surgery. Rev Bras Cir Cardiovasc 2008; 23: 169-174.
6. Farndale RW, Buttle DJ, Barret AJ. Improved quantitation and discrimination of sulphatedglycosaminoglycans by use of dimethylmethylene blue. Biochim Bio-phys Acta 1986; 883: 173-177.
7. Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem 1962; 4: 330-334.
8. Castro MO, Pomin VH, Santos LL, et al. A unique 2-sulfated β-galactan from the egg jelly of the sea urchin Glyptocidariscrenularis: conformational flexibility versus induction of the sperm acrosome reaction. J Biol Chem 2009; 284: 18790-18800.
9. Alves CS, Mourão PAS. Interaction of high molecular weight chondroitin sulfate from human aorta with plasma low density lipoproteins. Atherosclerosis 1988; 73: 113-124.
10. Tovar AMF, Cesar DCF, Leta GC, et al. Age-related changes in populations of aortic glycosaminoglycans. ArteriosclerThrombVascBiol 1998; 18: 604-614.
11. Tovar AMF, de Mattos DA, Stelling M P, et al: Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochimica Biophysica Acta 2005; 1740: 45-53.
12. Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and un-catalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-559.
13. Wessler S, Reimer SM, Sheps MC. Biological assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-946.
14. Herbert JM, Bernat A, Maffrand J P. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-2286.
15. Casu B, Guerrini M, Naggi A, et al. Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy. Arznei-mittelforschung 1996; 46: 472-477.
16. Mascellani G, Liverani L, Bianchini P. Analysis of heparin origin by HPLC quanti-tation of disaccharide components. Farmaco 1996; 51: 247-254.
17. Guerrini M, Naggi A, Guglieri S, et al. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectro-scopy. Anal Biochem 2005; 337: 35-47.
18. Guerrini M, Guglieri S, Casu B, et al. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for ver y hig h affinity induced by an unusual glu-curonic acid residue. J Biol Chem 2008; 283: 26662-26675.
19. Melo FR, Mourão PAS. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Thromb Haemost 2008; 99: 531-538.
20. Fonseca RJ, Oliveira SN, Melo FR, et al. Slight differences in sulfation of algal gal-actans account for differences in their anticoagulant and venous antithrombotic activities. ThrombHaemost 2008; 99: 539-545.
21. Fonseca RJ, Santos GR, Mourão PA. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications. Thromb Haemost 2009; 102: 829-836.
22. Fonseca RJ, Oliveira SN, Pomin VH, et al. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb Haemost 2010; 103: 994-1004.
23. Pacheco RG, Vicente C P, Zancan P, et al. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coagul Fibrinolysis 2000; 11: 563-573.
24. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.